World Asset Management Inc decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 0.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 512,716 shares of the biopharmaceutical company’s stock after selling 4,511 shares during the period. Pfizer accounts for approximately 0.6% of World Asset Management Inc’s portfolio, making the stock its 23rd largest holding. World Asset Management Inc owned approximately 8,620.92% of Pfizer worth $18,304,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. HL Financial Services LLC increased its position in shares of Pfizer by 1.1% in the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after acquiring an additional 35,744 shares in the last quarter. Hartford Financial Management Inc. increased its position in shares of Pfizer by 10.8% in the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 835 shares in the last quarter. Cadence Bank NA increased its position in shares of Pfizer by 1.4% in the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 1,428 shares in the last quarter. Majedie Asset Management Ltd grew its holdings in Pfizer by 7.9% during the 2nd quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after purchasing an additional 24,531 shares in the last quarter. Finally, Stanley Laman Group Ltd. grew its holdings in Pfizer by 373.7% during the 2nd quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after purchasing an additional 90,160 shares in the last quarter. 69.87% of the stock is currently owned by institutional investors and hedge funds.
Shares of Pfizer Inc. (NYSE PFE) traded up $0.54 on Friday, hitting $34.16. 47,300,000 shares of the stock traded hands, compared to its average volume of 25,460,000. The firm has a market cap of $203,620.00, a PE ratio of 9.70, a P/E/G ratio of 1.93 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a 12 month low of $31.67 and a 12 month high of $39.43.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The business’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.47 EPS. equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is 38.64%.
Pfizer announced that its board has approved a stock repurchase program on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its stock is undervalued.
PFE has been the subject of a number of recent analyst reports. SunTrust Banks reaffirmed a “hold” rating and set a $40.00 price target (up from $33.00) on shares of Pfizer in a report on Monday, January 29th. BMO Capital Markets reaffirmed a “buy” rating and set a $39.00 price target on shares of Pfizer in a report on Friday, November 10th. Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Thursday, October 26th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective on the stock in a research note on Monday, January 8th. Finally, Berenberg Bank set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $39.45.
In other news, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://ledgergazette.com/2018/02/12/world-asset-management-inc-has-18-30-million-position-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.